Biomarkers /
NTRK3
Overview
Neurotrophic tyrosine kinase, receptor, type 3 (NTRK3) is a gene that encodes a protein that belongs to the neurotrophic tyrosine kinase (NTRK) family. The protein functions in the phosphorylation of members of the MAP kinase pathway, cell differentiation, and the development of proprioceptive neurons. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, lung cancer, and skin cancer.
NTRK3 is altered in 2.75% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in NTRK3 are NTRK3 Mutation (2.35%), NTRK3 Fusion (0.15%), NTRK3 Amplification (0.11%), NTRK3 Loss (0.09%), and NTRK3-ETV6 Fusion (0.05%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of NTRK3 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.